Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 1;5(1):a003210.
doi: 10.1101/mcs.a003210. Print 2019 Feb.

Hematologic malignancies and Li-Fraumeni syndrome

Mahesh Swaminathan  1 , Sarah A Bannon  2 , Mark Routbort  3 , Kiran Naqvi  1 , Tapan M Kadia  1 , Koichi Takahashi  1 , Yesid Alvarado  1 , Farhad Ravandi-Kashani  1 , Keyur P Patel  3 , Richard Champlin  4 , Hagop Kantarjian  1 , Louise Strong  5 , Courtney D DiNardo  1
Affiliations
Review

Hematologic malignancies and Li-Fraumeni syndrome

Mahesh Swaminathan et al. Cold Spring Harb Mol Case Stud. .

Abstract

Li-Fraumeni syndrome (LFS) is an autosomal dominant condition associated with a high risk of a broad range of childhood- and adult-onset cancers. LFS is related to germline mutations of the tumor-suppressor gene TP53 The most common reported leukemia associated with LFS is hypodiploid acute lymphoblastic leukemia, but myeloid malignancies including acute myeloid leukemia (AML), chronic myeloid leukemia, and myelodysplastic syndrome (MDS) are also reported, often in the setting of therapy-related disease. We reviewed the clinicopathologic characteristics including cytogenetics and molecular analysis for seven adult patients with LFS and hematologic malignancies evaluated at the Hereditary Hematologic Malignancy Clinic (HHMC) at MD Anderson Cancer Center. We present this LFS review series to increase awareness of LFS for the appropriate diagnosis of both patients and potentially affected relatives, as well as provide experience with patient outcomes in this difficult to treat population.

Keywords: leukemia; multiple lineage myelodysplasia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Pedigree charts of (A) case 1, (B) case 2, (C) case 3, (D) case 4, (E) case 5, (F) case 6, and (G) case 7.
See this image and copyright information in PMC

References

    1. Ariffin H, Hainaut P, Puzio-Kuter A, Choong SS, Chan AS, Tolkunov D, Rajagopal G, Kang W, Lim LL, Krishnan S, et al. 2014. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li–Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci 111: 15497–15501. 10.1073/pnas.1417322111 - DOI - PMC - PubMed
    1. Asdahl PH, Ojha RP, Hasle H. 2017. Cancer screening in Li–Fraumeni syndrome. JAMA Oncol 3: 1645–1646. 10.1001/jamaoncol.2017.2459 - DOI - PubMed
    1. Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, et al. 2017. Baseline surveillance in Li–Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 3: 1634–1639. 10.1001/jamaoncol.2017.1968 - DOI - PMC - PubMed
    1. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. 2001. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20: 4621–4628. 10.1038/sj.onc.1204621 - DOI - PubMed
    1. Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. 2017. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li–Fraumeni syndrome Education and Early Detection (LEAD) clinic. Fam Cancer 17: 287–294. 10.1007/s10689-017-0034-6 - DOI - PubMed

Publication types

Substances